Professor Rocky Tuan Appointed To Orthocell Advisory Board

PERTH, Australia--(BUSINESS WIRE)--Regenerative medicine company Orthocell Limited (“the Company”) today announced the appointment of Professor Rocky Tuan to its Medical and Scientific Advisory Board (MSAB).

“The field of regenerative medicine is advancing at a rapid pace and Orthocell is a leader in musculoskeletal regeneration with its ground breaking tendon and soft tissue regeneration and repair products. I am excited to join the MSAB and look forward to contributing to the company’s continued development.”

The MSAB advises the Company on strategic matters such as clinical research and product development. It provides valuable expertise to Orthocell as it expands its unique tendon and soft tissue repair products into international markets and advances opportunities in tissue specific growth factors and laboratory manufactured human tendons.

Dr Tuan is a widely published and respected expert in regenerative medicine and stem cells. He is currently the Director of the Centre for Cellular and Molecular Engineering in the Department of Orthopaedic Surgery and Director of the Centre for Military Medicine Research, within the School of Medicine, at the University of Pittsburgh.

He is also the Executive Vice Chairman for Orthopaedic Research, and serves as the Arthur J. Rooney, Sr. Chair Professor in Sports Medicine, within the Department of Orthopaedic Surgery. He also holds a secondary appointment as a Professor within the Department of Bioengineering.

Dr Tuan’s research activities in musculoskeletal biology and tissue regeneration cover basic science and engineering, as well as translational and clinical applications focusing on orthopaedic research of the biological activities that are important for the development, growth, function, and health of musculoskeletal tissues and translating that into technologies and approaches that will regenerate and/or restore function to diseased and damaged skeletal tissues.

Dr Tuan said: “The field of regenerative medicine is advancing at a rapid pace and Orthocell is a leader in musculoskeletal regeneration with its ground breaking tendon and soft tissue regeneration and repair products. I am excited to join the MSAB and look forward to contributing to the company’s continued development.”

Dr Tuan’s past appointments include the National Institute of Health (NIH) as Chief of the Cartilage Biology and Orthopaedics Branch. In 2004, Dr Tuan received the Marshall Urist Award for Excellence in Tissue Regeneration Research of the Orthopaedic Research Society.

Orthocell CEO Mr Paul Anderson said: “We are delighted to have such an esteemed researcher as Dr Tuan join our MSAB. His expertise in the regenerative medicine space is a perfect fit for the company and we’re excited to attract such an experienced and well respected researcher in the regenerative medicine space from the US to advise the company moving forward.”

About Orthocell Limited

Orthocell is a commercial-stage, regenerative medicine company focused on regenerating mobility for patients and our ageing population by developing products for a variety of tendon, cartilage and soft tissue injuries. Orthocell’s portfolio of products include TGA-approved stem cell therapies Autologous Tenocyte Implantation (Ortho-ATI™) and Autologous Chondrocyte Implantation (Ortho-ACI™), which aim to regenerate damaged tendon and cartilage tissue. The Company’s other major product is Celgro™, a collagen medical device which facilitates tissue repair and healing in a variety of orthopaedic, reconstructive and surgical applications and is being readied for first regulatory approvals.